- Home
- SUPN
as 02-21-2025 4:00pm EST
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Upcoming Earnings Alert:
Get ready for potential market movements as Supernus Pharmaceuticals Inc. SUPN prepares to release earnings report on 25 Feb 2025.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 2.1B | IPO Year: | 2012 |
| Target Price: | $36.00 | AVG Volume (30 days): | 464.2K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.07 | EPS Growth: | 130.79 |
| 52 Week Low/High: | $25.53 - $40.28 | Next Earning Date: | 02-25-2025 |
| Revenue: | $651,972,000 | Revenue Growth: | 6.79% |
| Revenue Growth (this year): | 7.94% | Revenue Growth (next year): | -3.22% |
Stock Insider Trading Activity of Supernus Pharmaceuticals Inc. (SUPN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Feb 4 '25 | Sell | $39.70 | 9,477 | $376,236.90 | 10,149 | |
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Jan 27 '25 | Sell | $39.62 | 3,273 | $129,676.26 | 10,149 | |
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Dec 3 '24 | Sell | $36.68 | 21,495 | $788,436.60 | 10,149 |
Latest Supernus Pharmaceuticals Inc. News
SUPN Breaking Stock News: Dive into SUPN Ticker-Specific Updates for Smart Investing
Benzinga
3 days ago
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
MT Newswires
3 days ago
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57
MT Newswires
3 days ago
Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint
Argus Research
3 days ago
SUPN: Raising target price to $42.00
GlobeNewswire
3 days ago
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
GlobeNewswire
10 days ago
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Zacks
16 days ago
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
Pharmaceutical Technology
16 days ago
Supernus wins FDA approval for Parkinson’s pump on fourth try
Compare SUPN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SUPN Supernus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.